Use of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April–August 2016
Michelle S. Chevalier

, Brad J. Biggerstaff, Sridhar V. Basavaraju, M. Cheryl Bañez Ocfemia, Jose O. Alsina, Consuelo Climent-Peris, Robin R. Moseley, Koo-Whang Chung, Brenda Rivera-García, Melissa Bello-Pagán, Lisa L. Pate, Susan A. Galel, Phillip Williamson, and Matthew J. Kuehnert
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.S. Chevalier, S.V. Basavaraju, M.C. Bañez Ocfemia, R.R. Moseley, K.-W. Chung, M.J. Kuehnert); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (B.J. Biggerstaff); Banco de Sangre de Servicios Mutuos, San Juan, Puerto Rico (J.O. Alsina); Banco de Sangre del Centro Medico of the Administración de Servicios Médicos, San Juan (C. Climent-Peris); Puerto Rico Department of Health, San Juan (B. Rivera-García, M. Bello-Pagán); Roche Molecular Systems, Inc., Pleasanton, California, USA (L.L. Pate, S.A. Galel); Creative Testing Solutions, Tempe, Arizona, USA (P. Williamson)
Main Article
Table 2
Sensitivity analysis for Zika virus infections, computed from BSIS and ASEM cobas Zika ID-NAT results, Puerto Rico, April 3–August 12, 2016*
Mean viremia duration, d |
Total no. infections (95% CI) |
Population infected, % (95% CI) |
7 |
684,937 (585,924–816,000) |
18.82 (16.1–22.43) |
14 |
323,525 (276,756–385,431) |
8.89 (7.61–10.59) |
21 |
214,563 (183,546–255,619) |
5.89 (5.04–7.02) |
Main Article
Page created: April 17, 2017
Page updated: April 17, 2017
Page reviewed: April 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.